摘要
免疫检查点是免疫系统中抑制性的信号通路,通过与共刺激分子保持平衡,维持对自身组织的耐受,避免自身免疫反应。肿瘤的发生伴随着共抑制分子与相关配体的上调,引起T细胞功能衰退或耗竭,从而发生肿瘤细胞的免疫逃逸。针对抑制性受体与配体开发单抗药物,调节T细胞活性提高抗肿瘤免疫反应,已经取得较好的临床效果。对免疫调节信号通路采取联合治疗也体现出一定的协同作用。本文对肿瘤联合免疫治疗方案与协同作用评价进行综述,并对联合免疫治疗的可行性及免疫方案的选择进行展望。
Immune checkpoints are inhibitory signaling pathways in the immune system that maintain balance with co-stimulatory molecules,maintain tolerance to their own tissues,and avoid autoimmune responses.The development of tumors is accompanied by the upregulation of co-suppressor molecules and related ligands,causing the decline or exhaustion of T cell functions,which makes tumor cells excape immune surveillance.The development of monoclonal antibodies against inhibitory receptors and ligands to regulate T cell activity and improve antitumor immune responses have achieved promising clininal results.Combined treatment of immunomodulatory signaling pathways also showed a certain of synergy.This article summarizes the evaluation of combined tumor immunotherapy strategies and synergies,and outlooks the feasibility of combined immunotherapy and the selection of immunization strategies.
作者
张瑞
江涛
曾添筑
姚文兵
高向东
田浤
ZHANG Rui;JIANG Tao;ZENG Tianzhu;YAO Wenbing;GAO Xiangdong;TIAN Hong(Jiangsu Key Laboratory of Druggability of Biopharmaceuticals,School of Life Science and Technology,China Pharmaceutical University,Nanjing 210009,China)
出处
《中国药科大学学报》
CAS
CSCD
北大核心
2018年第4期383-391,共9页
Journal of China Pharmaceutical University
基金
国家自然科学基金资助项目(No.81573335,No.81673343)。